Mycobacterium (e.g., Mycobacterium Tuberculosis, Calmette-guerin Bacillus (i.e., Bcg), Etc.) Patents (Class 424/248.1)
-
Patent number: 7439041Abstract: Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described. Methods of using the reagents or antibodies to the reagents for detection, diagnosis, purification, therapy and prophylaxis for prions and prion-associated diseases are also described.Type: GrantFiled: August 13, 2004Date of Patent: October 21, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Melissa D. Michelitsch, Celine Y-H. Hu
-
Publication number: 20080248094Abstract: The invention relates to a liposome comprising a chloroform soluble and extractable total polar lipid of Mycobacterium spp, particularly a chloroform soluble extractable total polar lipid of Mycobacterium bovis BCG. The chloroform soluble and extractable polar lipid may comprise at least one of phosphatidylinositol (PI), phosphatidylinositol mannoside (PIM1), phosphatidylinositol dimannoside (PIM2), mono and dipalmitoylated forms of PIM1 and PIM2, phospholipid of 899 m/z, phosphatidylethanolamine and cardiolipid. The liposome may be prepared by drying chloroform soluble and extractable lipid and then hydrating said dried lipid at a temperature of 65 to 75° C. in water or phosphate buffered saline (PBS). The liposome may be used, for example, to activate dendritic cells to secrete cytokines and modulate an immune response in a mammal, or to direct an immune response to confer protection against a pathogen or a cancer.Type: ApplicationFiled: November 15, 2007Publication date: October 9, 2008Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: G. Dennis SPROTT, Lakshmi KRISHNAN, Subash SAD
-
Publication number: 20080248066Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: ApplicationFiled: August 11, 2006Publication date: October 9, 2008Applicant: Cerus CorporationInventors: Thomas W. Dubensky, Dirk G. Brockstedt, Keith S. Bahjat, John E. Hearst, David N. Cook, William S. Luckett
-
Publication number: 20080241182Abstract: Compositions and methods for preventing Mycobacterium infections, particularly persistent, latent Mycobactial infections, are provided. The compositions and methods utilize newly identified Mycobacterium genes (and/or corresponding gene products) that are necessary for survival of Mycobacteriae within a host.Type: ApplicationFiled: January 18, 2008Publication date: October 2, 2008Inventors: Sanjay K. Jain, S. Moises Hernandez-Abanto, Gyanu Lamichhane, William R. Bishai
-
Publication number: 20080233153Abstract: The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal against any target immunogen, and is particularly preferred for use with immunocontraceptive vaccines such as GnRH and PZP immunocontraceptive vaccines.Type: ApplicationFiled: August 16, 2007Publication date: September 25, 2008Inventors: Lowell A. Miller, Jack C. Rhyan
-
Patent number: 7422869Abstract: A method for diagnosing the presence in an animal of an infection due to a microorganism in which a test sample obtained from the animal is exposed to a population of the microorganism and the presence of binding of the microorganism by an antibody in the test sample is determined.Type: GrantFiled: February 1, 2007Date of Patent: September 9, 2008Assignee: University of Tennessee Research FoundationInventors: Shigetoshi Eda, Clarence A. Speer
-
Publication number: 20080213309Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.Type: ApplicationFiled: May 6, 2008Publication date: September 4, 2008Applicant: ALPHVAX, INC.Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
-
Publication number: 20080199495Abstract: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In one embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: May 24, 2007Publication date: August 21, 2008Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20080175869Abstract: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or virulence of a pathogenic mycobacterium, and methods of treating disease conditions associated with a pathogenic mycobacterium, particularly by administering an inhibitor of a mycobacterial sulfation pathway protein. The present invention further provides genetically modified mycobacteria having a defect in a sulfation pathway enzyme gene; and immunogenic compositions that include such genetically modified mycobacteria.Type: ApplicationFiled: October 18, 2007Publication date: July 24, 2008Inventors: Carolyn R. BERTOZZI, Spencer J. WILLIAMS, Joseph D. MOUGOUS
-
Publication number: 20080171002Abstract: Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.Type: ApplicationFiled: July 20, 2007Publication date: July 17, 2008Applicant: GOURMETCEUTICALS, LLCInventors: Jose Antonio Matji Tuduri, Antonio F. Guerrero Gomez-Pamo, Jose Luis Alonso Lebrero, Garrett Lindemann, Manuel Lopez Cabrera, Pedro Majano Rodriguez, Ricardo Moreno Otero, Diego Serrano Gomez, Angel Corbi Lopez, Samuel Martin Vilchez
-
Patent number: 7393539Abstract: A method is provided for identifying mycobacterial genes that are induced or up-regulated under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37° C. when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37° C. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.Type: GrantFiled: June 21, 2002Date of Patent: July 1, 2008Assignee: Health Protection AgencyInventors: Brian William James, Joanna Bacon, Philip Marsh
-
Patent number: 7393541Abstract: Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.Type: GrantFiled: May 13, 2004Date of Patent: July 1, 2008Assignee: Novavax, Inc.Inventors: D. Craig Wright, Joan Brisker, Mark A. Chambers
-
Patent number: 7393540Abstract: A method is provided for identifying mycobacterial genes that are induced or up-regulated under culture conditions that are nutrient-starving and which maintain mycobacterial latency, said conditions being obtainable by batch fermentation of a micobacterium for at least 20 days post-inoculation, when compared with culture conditions that are not nutrient-starving and which support exponential growth of said mycobacterium. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.Type: GrantFiled: July 4, 2002Date of Patent: July 1, 2008Assignee: Health Protection AgencyInventors: Brian William James, Philip Marsh, Tobias Hampshire
-
Publication number: 20080145383Abstract: Described is a method for making a pharmaceutical preparation comprising the solubilisation of a peptide mixture, characterized in that the peptide mixture is solubilized by an aqueous solution containing at least one organic acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid and halogenated or hydroxylated forms thereof.Type: ApplicationFiled: March 11, 2005Publication date: June 19, 2008Applicant: Intercell AGInventors: Wolfgang Zauner, Constantia Kritsch, Christa Heinrich-Cseh, Agnes Berger
-
Patent number: 7387886Abstract: Described is a prion protein, wherein said prion protein is a homodimer or heterodimer. The prion protein dimers are highly immunogenic capable of inducing an immune response in a mammal, thus useful for prophylactic or therapeutic vaccination against diseases associated with the infectious forms of prion proteins, PrPSc, i.e. transmissible spongiform encephalopathies. Moreover, antibodies generated by using the prion protein diners as an antigen, pharmaceutical composition containing the prion protein dimers or antibodies directed against said diners as well as DNA sequences encoding the prion protein diners are described.Type: GrantFiled: April 5, 2002Date of Patent: June 17, 2008Inventor: Hermann Schaetzl
-
Patent number: 7387773Abstract: The invention provides a vaccine comprising secreted protein derived from Mycobacterium avium subsp paratuberculosis (M. ptb) substantially free of whole organisms of that species either dead or alive. The secreted protein may be obtained from a culture of M. ptb with the microorganisms being removed by centrifugation and subsequent filtration. The vaccine may be used for vaccination against Johne's disease.Type: GrantFiled: August 7, 2002Date of Patent: June 17, 2008Assignees: Massey University, The New Zealand Meat Board, Wool Production Technologies LtdInventors: Alan Murray, Christine Dupont, Jeremy Lawrence Rae
-
Publication number: 20080131458Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.Type: ApplicationFiled: April 21, 2006Publication date: June 5, 2008Applicant: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Rajiv Indravadan Modi, Indravadan Arnbalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Patent number: 7364740Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 1, 2005Date of Patent: April 29, 2008Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 7361348Abstract: The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them.Type: GrantFiled: December 20, 2001Date of Patent: April 22, 2008Assignee: Institut PasteurInventors: Gilles Marchal, Felix Romain, Pascale Pescher
-
Patent number: 7344703Abstract: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or virulence of a pathogenic mycobacterium, and methods of treating disease conditions associated with a pathogenic mycobacterium, particularly by administering an inhibitor of a mycobacterial sulfation pathway protein. The present invention further provides genetically modified mycobacteria having a defect in a sulfation pathway enzyme gene; and immunogenic compositions that include such genetically modified mycobacteria.Type: GrantFiled: September 1, 2005Date of Patent: March 18, 2008Assignee: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Spencer J. Williams, Joseph D. Mougous
-
Patent number: 7335369Abstract: The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five M. tuberculosis antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.Type: GrantFiled: August 28, 2006Date of Patent: February 26, 2008Assignee: Corixa CorporationInventors: Steven G. Reed, Yasir A. Skeiky, Davin C. Dillon, Mark Alderson, Antonio Campos-Neto
-
Patent number: 7335480Abstract: The disclosed technology provides an enriched antibody population, highly specific for an antigen of a surface polysaccharide, from a mycobacterium. In a related embodiment, the antibody is enriched by having been raised in an environment that maintains antigenically active antigen. These antibodies may be used in an immunoreactive environment for detecting the presence of a mycobacterial infection in a sample from a subject.Type: GrantFiled: July 20, 2005Date of Patent: February 26, 2008Assignee: Chemogen, Inc.Inventors: Vladimir A. Koulchin, Elena V. Molokova, Jill L. Kerrick
-
Patent number: 7332340Abstract: The present invention relates to a process for identifying a novel target for use for the development of therapeutic modalities and drugs effective against tuberculosis comprising testing M. tuberculosis devR mutant strain for virulence in guinea pigs.Type: GrantFiled: February 8, 2002Date of Patent: February 19, 2008Assignee: The Director, All India Institute of Medical ScienceInventors: Jaya Sivaswami Tyagi, Vandana Kapur
-
Patent number: 7311922Abstract: The present invention relates to fusion proteins containing at least two Mycobacterium species antigens. In particular, it relates to nucleic acids encoding fusion proteins that include two or more individual M. tuberculosis antigens, which increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.Type: GrantFiled: October 10, 2000Date of Patent: December 25, 2007Assignee: Corixa CorporationInventors: Yasir Skeiky, Steven Reed, Raymond L. Houghton, Patricia D. McNeill, Davin C. Dillon, Michael J. Lodes
-
Patent number: 7300660Abstract: Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.Type: GrantFiled: October 27, 2003Date of Patent: November 27, 2007Assignee: The Regents of the University of CaliforniaInventors: Marcus A. Horwitz, Günter Harth, Bai-Yu Lee
-
Patent number: 7288261Abstract: Vaccine compositions for boosting immunity to mycobacteria when administered in mid-life in a subject who has been vaccinated neonatally or in early childhood with BCG and in whom protective immunity has waned comprise one or more purified immunogenic proteins from Mycobacterium tuberculosis from a group of 30 proteins that stimulate T cell immunity and interferon-? secretion. A preferred protein is Ag85A, the secreted product (SEQ ID NO:31) of the Rv3084c gene. Also disclosed are methods for boosting immunity in such BCG-vaccinated subjects comprising administering an effective amount of the above vaccine composition.Type: GrantFiled: July 10, 2001Date of Patent: October 30, 2007Assignee: Colorado State University Research FoundationInventors: Ian M. Orme, John T. Belisle
-
Patent number: 7279170Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.Type: GrantFiled: June 22, 2006Date of Patent: October 9, 2007Assignee: N.V. Innogenetics S.A.Inventors: Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
-
Publication number: 20070231301Abstract: Novel methods and drug products for treating superficial bladder cancer (SBC) are disclosed, which involve parenteral administration of low doses of a type 1 interferon. The doses used are subtherapeutic for other solid tumors. Use of the novel methods and products in combination with other therapies for SBC is also described.Type: ApplicationFiled: March 28, 2007Publication date: October 4, 2007Inventor: Stephen L. Warren
-
Patent number: 7276350Abstract: A method for diagnosing the presence in an animal of an infection due to a microorganism in which a test sample obtained from the animal is exposed to a population of the microorganism and the presence of binding of the microorganism by an antibody in the test sample is determined.Type: GrantFiled: April 27, 2004Date of Patent: October 2, 2007Assignee: University of Tennessee Research FoundationInventors: Shigetoshi Eda, Clarence A. Speer
-
Patent number: 7273602Abstract: An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided. A pharmaceutical composition which comprises a bacterial component as an effective ingredient is disclosed, which is used for immunotherapy in a patient suffering from a cancer or microbial infection, wherein the immunotherapy comprises eradicating the cancer cells or the microorganisms from the lymph nodes of the patient.Type: GrantFiled: July 19, 2002Date of Patent: September 25, 2007Inventor: Akira Hayashi
-
Patent number: 7261897Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.Type: GrantFiled: March 30, 2006Date of Patent: August 28, 2007Assignee: Corixa CorporationInventors: Yasir Skeiky, Steven Reed, Mark Alderson
-
Patent number: 7238359Abstract: The present invention relates to a PPE family antigenic protein Rv2430c of SEQ ID No. 1; a set of three high antigenic index peptides of SEQ ID Nos. 2 to 4; an antigenic ORF Rv2430c of SEQ ID No. 5 and lastly a method of inducing immune response against Mycobacterium tuberculosis in a subject in need thereof, said method comprising step of: introducing PPE antigenic protein Rv2430c of SEQ ID No. 1 into the subject and inducing immune response against Mycobacterium tuberculosis.Type: GrantFiled: August 9, 2005Date of Patent: July 3, 2007Assignees: An Autonomous Centre for the Department of Biotechnology, Ministry of Science & Technology, Government of IndiaInventors: Seyed Ehtesham Hasnain, Rakesh Kumar Choudhary
-
Patent number: 7238358Abstract: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.Type: GrantFiled: January 3, 2005Date of Patent: July 3, 2007Assignee: Corixa CorporationInventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
-
Patent number: 7186412Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.Type: GrantFiled: June 20, 2000Date of Patent: March 6, 2007Assignee: Corixa CorporationInventors: Yasir Skeiky, Steven Reed, Mark Alderson
-
Patent number: 7160548Abstract: Mycobacterium strains in which the erp gene is modified, and vaccine compositions comprising such Mycobacterium strains are provided. The modification of the erp gene may decrease the virulence and the persistence of the Mycobacterium strains.Type: GrantFiled: September 30, 2002Date of Patent: January 9, 2007Assignee: Institit PasteurInventors: Brigitte Gicquel, François-Xavier Berthet
-
Patent number: 7135280Abstract: Method of determining the efficacy of treatment for mycobacterial infection in an individual comprising determining in samples from the individual whether the level of T cells specific for a mycobacterial antigen has decreased after the treatment, thereby determining the efficacy of the treatment.Type: GrantFiled: January 8, 2002Date of Patent: November 14, 2006Assignee: Isis Innovation LimitedInventor: Ajit Lalvani
-
Patent number: 7122196Abstract: Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.Type: GrantFiled: March 15, 2005Date of Patent: October 17, 2006Assignee: Corixa CorporationInventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
-
Patent number: 7122195Abstract: This invention relates to recA mutant mycobacteria, particularly mutants of mycobacterial species which are members of the Mycobacterium tuberculosis complex, such as M. bovis BCG and M. tuberculosis. These mutant mycobacteria are useful as immunotherapteutic agents and vaccines for the treatment of a range of disorders, including tuberculosis.Type: GrantFiled: December 18, 2001Date of Patent: October 17, 2006Inventors: Kay Colston, legal representative, Eric Boettger, Peter Sander, Burkhard Springer, Jo Colston, deceased
-
Patent number: 7105170Abstract: Provided herein is an in vitro granuloma model and methods of its use. Methods of detecting and/or diagnosing latent tuberculosis in a subject are also provided, as are latency-specific antigens (and antibodies thereto), such as ?-crystallin, and methods of identifying and using such molecules. Also provided are immunostimulatory compositions, for instance for use in eliciting an immune response in a subject, such as an immune response to a latent tuberculosis infection. Kits for carrying out the provided methods are also described.Type: GrantFiled: January 7, 2002Date of Patent: September 12, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Frederick D. Quinn, Kristin A. Birkness, Manon Deslauriers, Peter King, David S. Beall
-
Patent number: 7094403Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.Type: GrantFiled: January 17, 2003Date of Patent: August 22, 2006Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
-
Patent number: 7090980Abstract: A method of detecting a specific acid-fast bacterium, wherein primers having nucleotide sequences homologous or complementary to the specific regions in the rRNAs of the specific acid-fast bacterium are used to specifically amplify only the rRNAs of the specific acid-fast bacterium.Type: GrantFiled: December 18, 2003Date of Patent: August 15, 2006Assignee: Tosoh CorporationInventors: Noriyoshi Masuda, Yuichi Isawa, Ryuichi Horie, Kiyoshi Yasukawa
-
Patent number: 7087713Abstract: Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA molecules encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Mycobacterium infection in patients and biological samples. Antibodies directed against such polypeptides are also provided. In addition, such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against Mycobacterium infection.Type: GrantFiled: February 26, 2001Date of Patent: August 8, 2006Assignee: Corixa CorporationInventors: Antonio Campos-Neto, Yasir Skeiky, Pamela Ovendale, Shyian Jen, Michael Lodes
-
Patent number: 7083798Abstract: The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source.Type: GrantFiled: November 13, 1997Date of Patent: August 1, 2006Assignee: Centenary Institute of Cancer Medicine and Cell BiologyInventor: Alan George Baxter
-
Patent number: 7083797Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.Type: GrantFiled: December 23, 2002Date of Patent: August 1, 2006Assignee: N.V. Innogenetics S.A.Inventors: Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
-
Patent number: 7083796Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.Type: GrantFiled: June 20, 2001Date of Patent: August 1, 2006Assignee: Corixa CorporationInventors: Yasir Skeiky, Steven Reed, Mark Alderson
-
Patent number: 7067136Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: GrantFiled: August 10, 2004Date of Patent: June 27, 2006Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 7064195Abstract: The present invention relates to fusion proteins of Mycobacterium tuberculosis antigens. In particular, it relates to two fusion proteins, each of which contains three individual M. tuberculosis antigens, and a fusion protein of two M. tuberculosis antigens, their coding sequences, and methods for their use in the treatment and prevention of tuberculosis.Type: GrantFiled: February 5, 2003Date of Patent: June 20, 2006Assignee: CorixaInventors: Yasir Skeiky, Mark Alderson, Antonio Campos-Neto
-
Patent number: 7037510Abstract: The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.Type: GrantFiled: March 13, 2001Date of Patent: May 2, 2006Assignee: Statens Serum InstitutInventors: Peter Andersen, Anja Weinreich Olsen, Rikke Louise Vinther Skjøt, Peter Birk Rasmussen
-
Patent number: 7026467Abstract: MLVA methods for strain discrimination among Mycobacterium tuberculosum strains are disclosed. Nine VNTR loci have been identified from genomic sequences of Mycobacterium tuberculosum strains and primer pairs suitable for amplifying the VNTR by PCR are disclosed. Polymorphisms at these loci were used to resolve genotypes into distinct groups. This sub-typing scheme is useful for the epidemiological study of Mycobacterium tuberculosum and may be applied to the local detection of the pathological causative agent of tuberculosum.Type: GrantFiled: July 21, 2003Date of Patent: April 11, 2006Assignee: Arizona Board of Regents, acting for and on behalf of, Northern Arizona UniversityInventors: Paul S. Keim, Robert Scott Spurgiesz, James M. Schupp
-
Patent number: 7026465Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.Type: GrantFiled: February 18, 2003Date of Patent: April 11, 2006Assignee: Corixa CorporationInventors: Yasir Skeiky, Jeff Guderian, Steven Reed